Ongeveer 13 uur geleden - Technische Universiteit Delft (TUD) - Delft
We are looking for talented individuals with a strong background and track-record in chemical engineering who strive to bring innovations in the field. We …
Prostate cancer is one of the most common cancers worldwide and leads to significant morbidity and mortality. While the disease can be cured in early stages, …
Prostate cancer is one of the most common cancers worldwide and leads to significant morbidity and mortality. While the disease can be cured in early stages, treatment options for more advanced stages of the disease are sparse and may be accompanied with severe side effects. Our research group develops novel and innovative imaging approaches and treatments to improve the outcome of prostate cancer patients. For this purpose we develop radiolabeled tumor targeting agents that specifically accumulate in prostate cancer lesions and allow radionuclide imaging and treatment of these lesions. These newly developed agents have been extensively tested in vitro in cell cultures and in vivo in animal models. The main focus of this PhD project will be to translate these noval tumor targeting agents into the clinics
One of the most important new therapeutic strategies for prostate cancer is treatment with radioactively labeled small molecules which specifically bind to the prostate-specific membrane antigen (PSMA) which is overexpressed in prostate cancer. So far, this so-called 177Lu-PSMA therapy has shown high efficacy in first trials in prostate cancer patients with advanced disease. In this project, this therapy will be applied personalized after dosimetric analysis in patients with oligo-metastatic disease, to evaluate, if patients with more localized disease could also profit from this therapy. In addition, effects of this therapy on the immune system will be evaluated and combinational treatments will be developed.
Tasks and responsibilities
Middels onderstaande knop kun je direct solliciteren op deze vacature.Reageer op deze vacature